J Korean Assoc Oral Maxillofac Surg 2017; 43(5): 312~317
Osteosarcoma of the jaws in Koreans: analysis of 26 cases
Hye-In Jeong1, Mi Jee Lee2,3, Woong Nam1,2, In-Ho Cha1,2, Hyung Jun Kim1,2
1Department of Oral and Maxillofacial Surgery, 2Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul, Korea,
3Colonical War Memorial Hospital, Ministry of Health, Suva, Fiji
Hyung Jun Kim
Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, 50-1 Yonsei-ro, Seodaemoon-gu, Seoul 03722, Korea
TEL: +82-2-2228-3132 FAX: +82-2-2227-7825
E-mail: kimoms@yuhs.ac
ORCID: http://orcid.org/0000-0002-3364-9995
Received June 22, 2017; Revised September 29, 2017; Accepted October 4, 2017.; Published online October 31, 2017.
© Korean Association of Oral and Maxillofacial Surgeons. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Objectives: In order to assess clinical behavior, response to treatment, and factors influencing prognosis of Korean patients with osteosarcoma of the jaws (OSJ).
Materials and Methods: A retrospective study of clinical, and pathological records of 26 patients with OSJ treated at the Department of Oral and Maxillofacial Surgery in Yonsei University Dental Hospital from 1990 to March 2017.
Results: Of 26 patients, there were 9 men (34.6%) and 17 women (65.4%). Twenty-one of 26 patients had osteosarcoma of the mandible, and 5 of 26 patients had osteosarcoma of the maxilla. The histopathology of OSJ is highly variable, ranging from chondroblastic type (6 out of 26), osteoblastic type (10 out of 26), fibroblastic type (2 out of 26), to the rare variants like mixed type, small cell osteosarcoma types and more. All patients underwent gross total excision and only a few patients underwent neoadjuvant chemotherapy. Postoperative chemotherapy was given to most of the patients as adjuvant treatment or in combination with radiotherapy. The overall survival rate was 73.1% with an overall 2-year survival rate of 83.3%. The overall 5-,10-,15-year survival rates in this study were 73.5%, 73.5%, 49%, respectively. Using Kaplan-Meier analysis with log rank tests, the size of tumor (T-stage), and resection margins were found to affect the survival rate significantly. The chemotherapy was not significantly associated with improved survival rate.
Conclusion: Surgical resection with a clear margin is the most important factor in disease survival. The role of chemotherapy and radiotherapy in OSJ remains controversial, and deserves further studies.
Keywords: Osteosarcoma, Maxillofacial, Survival, Mandible, Maxilla


Current Issue

31 October 2017
Vol. 43
No. 5 pp. 287~360

Indexed in